Cancer Immunotherapy: An Online Resource for Physician Fellows and Practicing Oncologists

Oncology fellows present key advances in immunotherapy for patients with cancer from the recent literature and discuss the findings and their implications with renowned experts in a journal club format.
Charles G. Drake, MD, PhD
person default
Anasuya Gunturi, MD, PhD
David F. McDermott, MD
Daniel Suzman, MD

Edition 1

Charles G. Drake, MD, PhD, and Daniel Suzman, MD, discuss 2 recent studies and a review article on cancer immunotherapy, as well as how the data relate to current therapeutic paradigms and future directions in the treatment of cancer.

Charles G. Drake, MD, PhD Daniel Suzman, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 3, 2014 Expiration: November 2, 2015

Edition 2

David F. McDermott, MD, and Anasuya Gunturi, MD, PhD, discuss 3 recent studies on cancer immunotherapy, as well as how the data relate to current therapeutic paradigms and future directions in the treatment of cancer.

person default Anasuya Gunturi, MD, PhD David F. McDermott, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 11, 2015 Expiration: March 10, 2016

Journal Article Reviews

In this review article, Charles G. Drake, MD, PhD; Evan J. Lipson, MD; and Julie Brahmer, MD, discuss the various clinical approaches and emerging data supporting immunotherapy in melanoma, non-small-cell lung cancer, and renal cell carcinoma.

Released: October 9, 2014

This slideset briefly summarizes key concepts and recent clinical results regarding immune checkpoint blockade across multiple tumor types including melanoma, lung cancer, kidney cancer, and others.

Released: October 29, 2014

Pembrolizumab is associated with a low incidence of grade 3/4 toxicities and confirmed response rates by RECIST criteria are similar regardless of previous ipilimumab treatment.

Released: October 9, 2014

Pembrolizumab is associated with a low incidence of grade 3/4 toxicities and similar response rates regardless of previous ipilimumab treatment.

Released: October 30, 2014

Ipilimumab after bone-directed radiotherapy failed to significantly prolong overall survival compared with placebo in the intent-to-treat analysis but showed evidence of antitumor activity and stronger benefit in patients with favorable prognostic factors.

Released: October 9, 2014

Ipilimumab after docetaxel failed to significantly prolong overall survival compared with placebo in the intent-to-treat analysis but showed evidence of antitumor activity and stronger benefit in patients with favorable prognostic factors.

Released: October 30, 2014

Median PFS of up to 4.2 months using RECIST, and up to 6.9 months using immune-related response criteria, with no dose-response relationship for PFS and median OS higher than predicted by PFS results.

Released: February 3, 2015

Nivolumab showed evidence of antitumor activity with an approximately 20% ORR across 3 dose levels and a median OS of 18-25 months in patients with clear cell metastatic RCC.

Released: February 24, 2015

MPDL3280A treatment well tolerated with high response rates among patients with elevated PD-L1 expression on tumor-infiltrating immune cells.

Released: February 3, 2015

MPDL3280A showed evidence of antitumor activity with a 43% ORR in patients with PD-L1 positive tumor-infiltrating immune cells.

Released: February 24, 2015

Nivolumab associated with 73% survival rate at 1 year and 58% reduction in risk of death compared with dacarbazine in treatment-naive patients with advanced BRAF wild-type melanoma.

Released: February 3, 2015

In the CheckMate 066 phase III study, the 1-year survival rate with nivolumab was 73% with a 58% reduction in the risk of death compared with DTIC in previously untreated patients.

Released: February 26, 2015

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?